Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15965382 | 0.90 | SRD5A1 (0.46) | SRD5A1TRPV1 | |
| SCHEMBL14288828 | 0.90 | SRD5A1 (0.46) | SRD5A1TRPV1 | |
| SCHEMBL28114020 | 0.86 | SRD5A1 (0.59) | SRD5A1TRPV1TRIM24CHRM1CYP17A1 | |
| SCHEMBL1924307 | 0.84 | SRD5A1 (0.42) | SRD5A1TRPV1TRIM24 | |
| SCHEMBL30661629 | 0.84 | SRD5A1 (0.42) | SRD5A1TRPV1TRIM24 | |
| SCHEMBL10890659 | 0.80 | TRIM24 (0.46) | SRD5A1TRPV1TRIM24CYP17A1CYP1A2 | |
| SCHEMBL5023390 | 0.80 | SRD5A1 (0.54) | SRD5A1TRPV1TRIM24CYP17A1CYP1A2 | |
| SCHEMBL6073803 | 0.79 | PBRM1 (0.46) | TRPV1TRIM24CYP17A1CYP1A2CYP19A1 | |
| SCHEMBL496099 | 0.79 | ATAD2 (0.51) | SRD5A1TRPV1TRIM24CYP17A1CYP1A2 | |
| SCHEMBL11263558 | 0.79 | SRD5A1 (0.55) | SRD5A1TRPV1TRIM24CHRM1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-2970198-B1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES FOR USE AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-2970198-B1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES FOR USE AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653618-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| EP-3212631-B1 | PYRAZOLYL-3,4-DIHYDROQUINOLIN-2-ONE ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3212631-B1 | PYRAZOLYL-3,4-DIHYDROQUINOLIN-2-ONE ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3212638-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037779-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5512594-A | ADMINISTERING TO TREAT A MEDICAL CONDITION MEDIATED BY ONE OR MORE LEUKOTRIENES | ZENECA LIMITED (GB) | 1996-04-30 | — | — | US | disclosed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | disclosed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | SRD5A1 60/4885TRPV1 4333/4885TRIM24 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.